| Eikon Therapeutics, Inc. |
10%+ Owner |
Common Stock |
2,294,653 |
|
|
06 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series A-1 Preferred Stock |
0 |
|
|
06 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series A Preferred Stock |
0 |
|
|
06 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series B-1 Preferred Stock |
0 |
|
|
06 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series B Preferred Stock |
0 |
|
|
06 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series C-1 Preferred Stock |
0 |
|
|
06 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series C Preferred Stock |
0 |
|
|
06 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series D Preferred Stock |
0 |
|
|
06 Feb 2026 |
Indirect |